Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Apexxnar“
Suchtreffer
Begriffe & Kennungen
Prevenar 20 (previously Apexxnar) · 4.8 · 9 Adverse reactions from clinical trials
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Additional information in special populations in studies with Prevenar 13
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Adverse reactions are listed by system organ class in decreasing order of frequency and seriousness. The frequ
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Adverse reactions from postmarketing experience
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · As Prevenar 20 contains the same 13 serotype-specific capsular polysaccharide conjugates and the same vaccine
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Blood and lymphatic system disorders Lymphadenopathy localised to the region of the vaccination site Immune sy
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Clinical trials were conducted in healthy infants 6 weeks to less than 15 months of age using a 3-dose schedul
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · In Study 1013, the local reactions and systemic events in the preterm subgroup (111 infants born at 34 to less
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · In participants 18 to 49 years of age in Studies 1007 and a Phase 3 trial B7471008 (Lot Consistency Study 1008
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · In the Phase 3 trial B7471014 (Study 1014), 831 participants 15 months to less than 18 years of age received a
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · In the Phase 3 trials, 4 263 participants received Prevenar 20. This included 1 798 participants 18 through 49
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Paediatric population
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Participants 18 years of age and older
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Participants 2 to < 18 years of age with HSCT have similar frequencies of adverse reactions in Table 1, except
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Participants 6 to < 18 years of age with HIV infection have similar frequencies of adverse reactions in Table
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Participants 6 to < 18 years of age with SCD have similar frequencies of adverse reactions in Table 1, except
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Participants 6 weeks to less than 15 months of age
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Participants aged 15 months to less than 18 years of age
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Participants in the Phase 3 trial B7471007 (Pivotal Study 1007) were evaluated for adverse events for 1 month
Eintrag öffnenPrevenar 20 (previously Apexxnar) · 4.8 · Phase 3 Study B7471006 (Study 1006) evaluated Prevenar 20 in participants ≥ 65 years of age with varying prior
Eintrag öffnen